Research programme: amyotrophic lateral sclerosis therapeutics - Iron Horse TherapeuticsAlternative Names: EPH receptor 4 inhibitors - Iron Horse Therapeutics; EphA4 inhibitors - Iron Horse Therapeutics; Ephrin type A receptor 4 inhibitors - Iron Horse Therapeutics
Latest Information Update: 19 Nov 2015
At a glance
- Originator Sanford-Burnham Medical Research Institute
- Developer Iron Horse Therapeutics; Sanford Burnham Prebys Medical Discovery Institute
- Class Small molecules
- Mechanism of Action Eph family receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis